IRIS Registry EHR data from patients with wet AMD who initiated brolucizumab were analyzed in this study.~Identification period of the index date (index period): The patients fulfilling the selection criteria was identified~Index date: Defined as the date of the earliest brolucizumab injection~Study Period: The period from the first patient eye exposure to brolucizumab to the last follow-up recorded~Pre-index period: The period 36 months prior to the index date. Data within 36 months prior to the index date will be used to assess baseline characteristics.~Post-index period: The period 180 days after the index date
This study was a retrospective cohort study of patients to assess the early insights into real-world safety among wet AMD patients initiating brolucizumab. Evidence was generated to describe their patient characteristics and clinical outcomes. The study was conducted using the IRIS Registry.